World News

State of Michigan Retirement System Raises Position in Exelixis, Inc. (NASDAQ:EXEL)

State of Michigan Retirement System Raises Position in Exelixis, Inc. (NASDAQ:EXEL)

State of Michigan Retirement System grew its place in Exelixis, Inc. (NASDAQ:EXEL – Get Score) by 1.2% within the 4th quarter, in line with its most up-to-date disclosure with the SEC. The fund owned 82,116 shares of the biotechnology firm’s inventory after shopping for a further 1,000 shares throughout the interval. State of Michigan Retirement System’s holdings in Exelixis had been value $1,317,000 as of its most up-to-date SEC submitting.

A number of different massive traders have additionally purchased and offered shares of the corporate. Fulton Financial institution N.A. elevated its holdings in Exelixis by 6.3% throughout the third quarter. Fulton Financial institution N.A. now owns 10,765 shares of the biotechnology firm’s inventory valued at $169,000 after shopping for a further 640 shares over the last quarter. CWM LLC elevated its holdings in Exelixis by 12.8% throughout the third quarter. CWM LLC now owns 6,053 shares of the biotechnology firm’s inventory valued at $95,000 after shopping for a further 687 shares over the last quarter. Healthcare of Ontario Pension Plan Belief Fund elevated its holdings in Exelixis by 5.6% throughout the third quarter. Healthcare of Ontario Pension Plan Belief Fund now owns 13,253 shares of the biotechnology firm’s inventory valued at $208,000 after shopping for a further 703 shares over the last quarter. US Bancorp DE elevated its holdings in Exelixis by 1.1% throughout the third quarter. US Bancorp DE now owns 75,522 shares of the biotechnology firm’s inventory valued at $1,184,000 after shopping for a further 786 shares over the last quarter. Lastly, Louisiana State Workers Retirement System elevated its holdings in Exelixis by 0.9% throughout the fourth quarter. Louisiana State Workers Retirement System now owns 86,400 shares of the biotechnology firm’s inventory valued at $1,386,000 after shopping for a further 800 shares over the last quarter. 84.74% of the inventory is owned by hedge funds and different institutional traders.

Insider Exercise at Exelixis

In different information, Director Jack L. Wyszomierski offered 15,300 shares of the inventory in a transaction dated Friday, March tenth. The shares had been offered at a mean worth of $16.61, for a complete transaction of $254,133.00. Following the sale, the director now owns 317,467 shares of the corporate’s inventory, valued at $5,273,126.87. The sale was disclosed in a submitting with the Securities & Change Fee, which may be accessed by way of the SEC web site. In different Exelixis information, Director Jack L. Wyszomierski offered 15,300 shares of the inventory in a transaction that occurred on Friday, March tenth. The shares had been offered at a mean worth of $16.61, for a complete worth of $254,133.00. Following the transaction, the director now immediately owns 317,467 shares within the firm, valued at $5,273,126.87. The sale was disclosed in a authorized submitting with the Securities & Change Fee, which is accessible by way of the SEC web site. Additionally, EVP Patrick J. Haley offered 25,000 shares of the agency’s inventory in a transaction that occurred on Monday, February sixth. The inventory was offered at a mean worth of $17.37, for a complete transaction of $434,250.00. Following the transaction, the chief vice chairman now owns 254,414 shares within the firm, valued at $4,419,171.18. The disclosure for this sale may be discovered right here. During the last quarter, insiders offered 237,100 shares of firm inventory valued at $4,212,089. 2.90% of the inventory is owned by firm insiders.

Exelixis Worth Efficiency

EXEL opened at $19.64 on Friday. The agency has a fifty day transferring common worth of $18.06 and a 200 day transferring common worth of $17.01. Exelixis, Inc. has a 1 yr low of $14.87 and a 1 yr excessive of $23.29. The inventory has a market cap of $6.37 billion, a P/E ratio of 34.46, a P/E/G ratio of 0.83 and a beta of 0.68.

Exelixis (NASDAQ:EXEL – Get Score) final posted its earnings outcomes on Tuesday, February seventh. The biotechnology firm reported ($0.09) earnings per share (EPS) for the quarter, lacking the consensus estimate of ($0.05) by ($0.04). The agency had income of $423.92 million throughout the quarter, in comparison with analyst estimates of $418.71 million. Exelixis had a internet margin of 11.31% and a return on fairness of seven.54%. The enterprise’s income for the quarter was down 6.0% on a year-over-year foundation. Throughout the identical quarter within the prior yr, the agency earned $0.29 earnings per share. Equities analysts anticipate that Exelixis, Inc. will put up 0.66 EPS for the present yr.

Wall Road Analysts Forecast Development

Quite a few brokerages have commented on EXEL. Piper Sandler reaffirmed an “obese” score and set a $32.00 goal worth on shares of Exelixis in a report on Wednesday, February eighth. Credit score Suisse Group started protection on shares of Exelixis in a report on Thursday, January twenty sixth. They set an “outperform” score and a $29.00 goal worth for the corporate. EF Hutton Acquisition Co. I reiterated a “purchase” score and issued a $24.00 worth goal on shares of Exelixis in a analysis report on Friday, March third. JMP Securities dropped their worth goal on shares of Exelixis from $25.00 to $24.00 and set a “market outperform” score for the corporate in a analysis report on Thursday, January nineteenth. Lastly, Cowen dropped their worth goal on shares of Exelixis from $21.00 to $20.00 in a analysis report on Monday, January ninth. One analyst has rated the inventory with a maintain score and 9 have given a purchase score to the corporate’s inventory. In line with MarketBeat.com, Exelixis has a consensus score of “Reasonable Purchase” and a consensus worth goal of $25.92.

Exelixis Profile

(Get Score)

Exelixis, Inc operates as an oncology firm, which focuses on discovering, growing, and commercialization of recent medicines for difficult-to-treat cancers. Its merchandise embrace cabometyx, cometriq, and cotellic. The corporate was based by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

See Additionally

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)



Obtain Information & Scores for Exelixis Every day – Enter your e-mail deal with beneath to obtain a concise each day abstract of the newest information and analysts’ scores for Exelixis and associated firms with MarketBeat.com’s FREE each day e-mail publication.

Iran Leader: US’ New Middle East Scheme Completely Failed

Mugen

Semus Wealth Partners LLC Has $313,000 Position in The Home Depot, Inc. (NYSE:HD)

Mugen

Iran FM Urges The UN Chief To Force Israel To Stop Gaza Genocide

Mugen
dnka xsnl mcpa csnl